59 related articles for article (PubMed ID: 23996617)
1. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
4. Exploring the impact of MiR-92a-3p on FOLFOX chemoresistance biomarker genes in colon cancer cell lines.
Escalante PI; Quiñones LA; Contreras HR
Front Pharmacol; 2024; 15():1376638. PubMed ID: 38659583
[No Abstract] [Full Text] [Related]
5. KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2.
Ye F; Xie Y; Lin M; Liu Y; Fang Y; Chen K; Zhang Y; Ding Y
Mol Cell Biochem; 2024 Mar; 479(3):629-642. PubMed ID: 37140813
[TBL] [Abstract][Full Text] [Related]
6. Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3.
Li G; Liu H; Yu Y; Wang Q; Yang C; Yan Y; Wang F; Mao Y
EBioMedicine; 2024 Apr; 102():105041. PubMed ID: 38484555
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of ERCC2 gene in head and neck cancer is associated with aggressive tumors: a systematic review and case-control study.
Zafeer M; Mahjabeen I; Kayani MA
Int J Biol Markers; 2016 Feb; 31(1):e17-25. PubMed ID: 26659720
[TBL] [Abstract][Full Text] [Related]
8. High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer.
Kim DH; Lee H; Kim DH; Chae SW; Sohn JH; Kim K; Do SI
Oncol Lett; 2017 Oct; 14(4):4995-5003. PubMed ID: 28943968
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer.
Chuang JP; Tsai HL; Chen PJ; Chang TK; Su WC; Yeh YS; Huang CW; Wang JY
Cells; 2022 Nov; 11(23):. PubMed ID: 36497002
[TBL] [Abstract][Full Text] [Related]
10. Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.
Massai L; Cirri D; Marzo T; Messori L
Cancer Drug Resist; 2022; 5(1):1-14. PubMed ID: 35582525
[TBL] [Abstract][Full Text] [Related]
11. Decreased ATM Function Causes Delayed DNA Repair and Apoptosis in Common Variable Immunodeficiency Disorders.
Hargreaves CE; Salatino S; Sasson SC; Charlesworth JEG; Bateman E; Patel AM; Anzilotti C; Broxholme J; Knight JC; Patel SY
J Clin Immunol; 2021 Aug; 41(6):1315-1330. PubMed ID: 34009545
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence.
Wang YY; Fang PT; Su CW; Chen YK; Huang JJ; Huang MY; Yuan SF
Oncol Lett; 2021 Jun; 21(6):450. PubMed ID: 33868488
[TBL] [Abstract][Full Text] [Related]
13. ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation.
Huang MY; Lee HH; Huang CW; Huang CM; Ma CJ; Yin TC; Tsai HL; Chai CY; Chen YT; Wang JY
Oncol Lett; 2020 Nov; 20(5):212. PubMed ID: 32963618
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer.
Luo SS; Liao XW; Zhu XD
Biomed Res Int; 2018; 2018():6204684. PubMed ID: 30417012
[TBL] [Abstract][Full Text] [Related]
15. The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis.
Liu J; Li H; Sun L; Feng X; Wang Z; Yuan Y; Xing C
Biomed Res Int; 2018; 2018():9651320. PubMed ID: 29568775
[TBL] [Abstract][Full Text] [Related]
16. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
Purim O; Beny A; Inbar M; Shulman K; Brenner B; Dudnik E; Bokstein F; Temper M; Limon D; Matceyevsky D; Sarid D; Segal A; Semenisty V; Brenner R; Peretz T; Idelevich E; Pelles-Avraham S; Meirovitz A; Figer A; Russell K; Voss A; Dvir A; Soussan-Gutman L; Hubert A
Target Oncol; 2018 Apr; 13(2):217-226. PubMed ID: 29353436
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer.
Huang MY; Tsai HL; Huang JJ; Wang JY
Transl Oncol; 2016 Aug; 9(4):340-7. PubMed ID: 27567958
[TBL] [Abstract][Full Text] [Related]
19. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
Rodrigues D; Longatto-Filho A; Martins SF
Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
[TBL] [Abstract][Full Text] [Related]
20. Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.
Li MX; Bi XY; Zhao H; Huang Z; Han Y; Zhao DB; Zhao JJ; Cai JQ
Chin Med J (Engl); 2016 Mar; 129(5):586-93. PubMed ID: 26904994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
